Table 1.
Demographic and baseline clinical characteristics of NET patients.
| Characteristic | 100mCi TATE (n=6) | 30mCi EBTATE (n=7) | 50mCi EBTATE (n=6) | 100mCi EBTATE (n=14) |
|---|---|---|---|---|
| Male/Female | 4/2 | 5/2 | 4/2 | 7/7 |
| Age-y | 43 ± 12 | 55 ± 7 | 55 ± 10 | 50 ± 10 |
| Primary tumor site | ||||
| Pancreas | 3 | 3 | 3 | 7 |
| Duodenum | 0 | 2 | 1 | 3 |
| Rectum | 0 | 1 | 0 | 2 |
| Lung | 1 | 0 | 1 | 0 |
| Ovary | 1 | 0 | 0 | 0 |
| CUP | 1 | 0 | 0 | 1 |
| MEN1 | 0 | 0 | 1 | 0 |
| Paraganglioma | 0 | 0 | 0 | 1 |
| Pheochromocytoma | 0 | 1 | 0 | 0 |
| Tumor grade | ||||
| G1 | 3 | 2 | 1 | 3 |
| G2 | 2 | 4 | 4 | 10 |
| G3 | 1 | 1 | 1 | 1 |
| Number of lesions | ||||
| 1–10 | 1 | 4 | 2 | 6 |
| 11–20 | 2 | 1 | 2 | 1 |
| >20 | 3 | 2 | 2 | 7 |
| Metastases | ||||
| Liver | 6 | 7 | 5 | 14 |
| Bone | 2 | 3 | 2 | 6 |
| Lymph node | 4 | 3 | 2 | 5 |
| Lung | 1 | 1 | 1 | 3 |
| Prior treatment | ||||
| Surgery | 1 | 5 | 2 | 7 |
| Somatostatin analog | 5 | 2 | 5 | 5 |
| Everolimus | 1 | 0 | 3 | 1 |
| TKI* | 1 | 3 | 5 | 9 |
| Chemotherapy | 3 | 3 | 3 | 6 |
| Radiotherapy | 0 | 0 | 1 | 1 |
| TACE | 1 | 1 | 1 | 3 |
| Disease course(month) | 51 ± 28 | 51 ± 36 | 58 ± 26 | 55 ± 25 |
*
Tyrosine kinase inhibitor